ArticleLupus science & medicine2026
Inhibition of STING modulates dendritic cell responses and ameliorates podocyte injury in SLE.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSLE features aberrant type I interferon production, with the stimulator of interferon genes (STING) pathway acting as a key upstream driver. However, its expression patterns in patients with SLE and contributions to clinical phenotypes and tissue injury remain insufficiently defined.
methodsThe proportion of STING-positive cells in peripheral blood mononuclear cells (PBMCs) from 28 patients with SLE and 15 healthy controls was analysed alongside clinical and serological features. Glomerular STING expression and podocyte injury were assessed in kidney biopsies from 39 patients with lupus nephritis (LN) and circulating and renal STING expression was compared in a paired cohort. The therapeutic effects of STING inhibitor C176 were evaluated in MRL/lpr mice by examining kidney pathology, proteinuria, function, immune cell subsets and podocyte injury. STING-mediated regulation of dendritic cell (DC) activation and plasmacytoid DC (pDC) differentiation was further investigated in vivo and in vitro.
resultsSTING expression was significantly elevated in PBMCs from patients with SLE and kidney tissues from patients with LN, particularly in proliferative LN and correlated with glomerular proliferation and decreased synaptopodin expression, suggesting an association with podocyte injury. STING activation promoted DC activation and pDC differentiation. Furthermore, conditioned media from STING-activated DCs induced podocyte apoptosis and reduced synaptopodin expression, effects attenuated by STING inhibition, indicating that STING activation in DCs promotes podocyte injury and disrupts podocyte homeostasis in a paracrine manner. C176 treatment in MRL/lpr mice significantly alleviated splenomegaly, proteinuria, kidney inflammation and renal dysfunction, while restoring podocyte integrity and reshaping immune responses.
conclusionOur findings suggest a potential role for STING in the interplay between immune dysregulation and podocyte injury in lupus. Pharmacological STING inhibition modulates DC responses and partially protects podocytes and renal structure, supporting STING as a promising therapeutic target for SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.